Cargando…

Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia

OBJECTIVE: To compare the efficacy of metformin plus megestrol acetate (MA) with that of MA alone for treating endometrial atypical hyperplasia (EAH). METHODS: This pilot study included 16 EAH patients who met at least one metabolic syndrome (MS) criterion and received either adjunctive metformin pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shan, Weiwei, Wang, Chao, Zhang, Zhenbo, Gu, Chao, Ning, Chengcheng, Luo, Xuezhen, Zhou, Qiongjie, Chen, Xiaojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102740/ https://www.ncbi.nlm.nih.gov/pubmed/25045434 http://dx.doi.org/10.3802/jgo.2014.25.3.214

Ejemplares similares

Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin as a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma
por: Jing, Chu-Yu, et al.
Publicado: (2022)

Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol
por: Zhao, Xin, et al.
Publicado: (2022)

Effectiveness of Megestrol for the Treatment of Patients with Atypical Endometrial Hyperplasia or Endometrial Endometrioid Adenocarcinoma (Stage IA, Well Differentiated)
por: Akhavan, Setareh, et al.
Publicado: (2021)

Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients
por: Wu, Pengfei, et al.
Publicado: (2022)

Megestrol acetate in cachexia and anorexia
por: Yeh, Shing-shing, et al.
Publicado: (2006)

Effects of Weight Status and Related Metabolic Disorders on Fertility-Sparing Treatment Outcomes in Endometrial Atypical Hyperplasia and Endometrial Cancer: A Retrospective Study
por: Liu, Sijia, et al.
Publicado: (2022)

Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models
por: Yang, Bingyi, et al.
Publicado: (2016)

Pterostilbene, a natural phenolic compound, synergizes the antineoplastic effects of megestrol acetate in endometrial cancer
por: Wen, Wei, et al.
Publicado: (2017)

Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019)

Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients
por: Yang, Bingyi, et al.
Publicado: (2018)

Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome
por: Wang, Lulu, et al.
Publicado: (2021)

PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia
por: Xue, Yu, et al.
Publicado: (2023)

The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer
por: Guan, Jun, et al.
Publicado: (2022)

Megestrol Acetate-Induced Symptomatic Hypogonadism in a Male Patient
por: Munshi, Lubna Bashir, et al.
Publicado: (2018)

Megestrol acetate for cachexia–anorexia syndrome. A systematic review
por: Ruiz‐García, Vicente, et al.
Publicado: (2018)

New Biopolymer Nanoparticles Improve the Solubility of Lipophilic Megestrol Acetate
por: Lachowicz, Malwina, et al.
Publicado: (2016)

Exogenous Cushing’s Syndrome, Hypogonadism and Diabetes Secondary to Megestrol Acetate
por: Baby, Merilyn, et al.
Publicado: (2021)

Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial)
por: Mitsuhashi, Akira, et al.
Publicado: (2020)

Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women
por: Uccella, Stefano, et al.
Publicado: (2022)

Influence of megestrol acetate on nutrition, inflammation and quality of life in dialysis patients
por: Gołębiewska, Justyna E., et al.
Publicado: (2011)

Hydrophilic and Functionalized Nanographene Oxide Incorporated Faster Dissolving Megestrol Acetate
por: Islam, Mohammad Saiful, et al.
Publicado: (2021)

Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia
por: Matsuzaki, Toshiya, et al.
Publicado: (2018)

Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases
por: Read, William L., et al.
Publicado: (2017)

Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914)
por: Xu, Zhiying, et al.
Publicado: (2022)

Menopausal Status Combined with Serum CA125 Level Significantly Predicted Concurrent Endometrial Cancer in Women Diagnosed with Atypical Endometrial Hyperplasia before Surgery †
por: Lou, Yaochen, et al.
Publicado: (2021)

Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension
por: Deschamps, Benoit, et al.
Publicado: (2009)

Megestrol Acetate Induced Paradoxical Embolism in a Sickle Cell Disease Patient
por: Dominguez, Lisette, et al.
Publicado: (2019)

SUN-031 Megestrol Acetate for Bodybuilding Resulting in Abrupt Hypothalamic-Pituitary Dysfunction
por: Lessard, Kimberly Kochersperger, et al.
Publicado: (2020)

Characterizing the Drug-Release Enhancement Effect of Surfactants on Megestrol-Acetate-Loaded Granules
por: Katona, Gábor, et al.
Publicado: (2022)

Conservative treatment for atypical endometrial hyperplasia: what is the most effective therapeutic method?
por: Kim, Mi Kyoung, et al.
Publicado: (2014)

The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia
por: Chen, Xiaojun
Publicado: (2019)

Massively parallel sequencing of endometrial lavage specimens for the detection of cancer-associated mutations in atypical and non-atypical endometrial hyperplasia
por: Weng, Cindy Hsuan, et al.
Publicado: (2022)

Metformin for endometrial hyperplasia: a Cochrane protocol
por: Clement, Naomi S, et al.
Publicado: (2016)

A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients.
por: McMillan, D. C., et al.
Publicado: (1997)

Precipitation Reaction of SDS and Potassium Salts in Flocculation of a Micronized Megestrol Acetate Suspension
por: Hejazi, Seyed Mahdi, et al.
Publicado: (2013)

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
por: Lv, Mu, et al.
Publicado: (2022)

Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
por: Zhou, Shuang, et al.
Publicado: (2021)

Estrogen and high-fat diet induced alterations in C57BL/6 mice endometrial transcriptome profile
por: Cheng, Yali, et al.
Publicado: (2017)

Lymph node dissection in atypical endometrial hyperplasia
por: Taşkın, Salih, et al.
Publicado: (2017)

A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss
por: McMillan, D C, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_420dnv9cv6tgf7r3547uaiqdgk